142 related articles for article (PubMed ID: 38600434)
1. International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.
Liem X; de Baère T; Vivar OI; Seiwert TY; Shen C; Pápai Z; Moreno V; Takácsi-Nagy Z; Helfferich F; Thariat J; Gooi Z; Yom SS; Bossi P; Ferris RL; Hackman TG; Le Tourneau C; Rodriguez J; Hoffmann C
Head Neck; 2024 Jun; 46(6):1253-1262. PubMed ID: 38600434
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx.
Hoffmann C; Calugaru V; Borcoman E; Moreno V; Calvo E; Liem X; Salas S; Doger B; Jouffroy T; Mirabel X; Rodriguez J; Chilles A; Bernois K; Dimitriu M; Fakhry N; Hee Kam SW; Le Tourneau C
Eur J Cancer; 2021 Mar; 146():135-144. PubMed ID: 33607477
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas.
Bonvalot S; Le Pechoux C; De Baere T; Kantor G; Buy X; Stoeckle E; Terrier P; Sargos P; Coindre JM; Lassau N; Ait Sarkouh R; Dimitriu M; Borghi E; Levy L; Deutsch E; Soria JC
Clin Cancer Res; 2017 Feb; 23(4):908-917. PubMed ID: 27998887
[No Abstract] [Full Text] [Related]
4. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Bonvalot S; Rutkowski PL; Thariat J; Carrère S; Ducassou A; Sunyach MP; Agoston P; Hong A; Mervoyer A; Rastrelli M; Moreno V; Li RK; Tiangco B; Herraez AC; Gronchi A; Mangel L; Sy-Ortin T; Hohenberger P; de Baère T; Le Cesne A; Helfre S; Saada-Bouzid E; Borkowska A; Anghel R; Co A; Gebhart M; Kantor G; Montero A; Loong HH; Vergés R; Lapeire L; Dema S; Kacso G; Austen L; Moureau-Zabotto L; Servois V; Wardelmann E; Terrier P; Lazar AJ; Bovée JVMG; Le Péchoux C; Papai Z
Lancet Oncol; 2019 Aug; 20(8):1148-1159. PubMed ID: 31296491
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.
Jiménez-Labaig P; Rullan A; Braña I; Hernando-Calvo A; Moreno V; Doger B; Bitar G; Ap Dafydd D; Melcher A; Harrington KJ
Cancer Treat Rev; 2024 Jun; 127():102746. PubMed ID: 38696902
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).
Mañós M; Giralt J; Rueda A; Cabrera J; Martinez-Trufero J; Marruecos J; Lopez-Pousa A; Rodrigo JP; Castelo B; Martínez-Galán J; Arias F; Chaves M; Herranz JJ; Arrazubi V; Baste N; Castro A; Mesía R
Oral Oncol; 2017 Jul; 70():58-64. PubMed ID: 28427761
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2).
Rueda A; Giralt J; Mañós M; Lozano A; Sistiaga A; García-Miragall E; Cacicedo J; Esteban F; Scola B; Contreras J; Ruiz A; Carral A; Sanchez-Aniceto G; Pastor M; Herranz JJ; Bernal M; Mesía R
Oral Oncol; 2017 Jul; 70():65-72. PubMed ID: 28427762
[TBL] [Abstract][Full Text] [Related]
8. NBTXR3 Radiotherapy-Activated Functionalized Hafnium Oxide Nanoparticles Show Efficient Antitumor Effects Across a Large Panel of Human Cancer Models.
Zhang P; Marill J; Darmon A; Mohamed Anesary N; Lu B; Paris S
Int J Nanomedicine; 2021; 16():2761-2773. PubMed ID: 33880022
[TBL] [Abstract][Full Text] [Related]
9. Imaging Features of Intratumoral Injection of NBTXR3 for Head and Neck Squamous Cell Carcinoma Lymph Node Metastases.
Ginat DT; Juloori A; Vivar OI; Farber LA; Gooi Z; Rosenberg AJ
Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140557
[TBL] [Abstract][Full Text] [Related]
10. Latin American Consensus on the Treatment of Head and Neck Cancer.
Matos LL; Kowalski LP; Chaves ALF; de Oliveira TB; Marta GN; Curado MP; de Castro Junior G; Farias TP; Bardales GS; Cabrera MA; Capuzzo RC; de Carvalho GB; Cernea CR; Dedivitis RA; Dias FL; Estefan AM; Falco AH; Ferraris GA; Gonzalez-Motta A; Gouveia AG; Jacinto AA; Kulcsar MAV; Leite AK; Lira RB; Mak MP; De Marchi P; de Mello ES; de Matos FCM; Montero PH; de Moraes ED; de Moraes FY; Morais DCR; Poenitz FM; Poitevin A; Riveros HO; Sanabria Á; Ticona-Castro M; Vartanian JG; Viani G; Vines EF; William Junior WN; Conway D; Virani S; Brennan P;
JCO Glob Oncol; 2024 Apr; 10():e2300343. PubMed ID: 38603656
[TBL] [Abstract][Full Text] [Related]
11. Endobronchial ultrasound-guided injection of NBTXR3 radio-enhancing nanoparticles into mediastinal and hilar lymph nodes: a swine model to evaluate feasibility, injection technique, safety, nanoparticle retention and dispersion.
Casal RF; Schwalk AJ; Fowlkes N; Aburto RR; Norton W; Dixon KA; Lin S; Shaitelman SF; Chintalapani G; Hill L
J Thorac Dis; 2020 May; 12(5):2317-2324. PubMed ID: 32642136
[TBL] [Abstract][Full Text] [Related]
12. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
13. [Doubling complete histological response in sarcomas with radiation therapy using nanoparticles (Hafnium oxide, NBTXR3), a phase III trial].
Khalladi N; Thariat J
Bull Cancer; 2019 Dec; 106(12):1070-1072. PubMed ID: 31761268
[No Abstract] [Full Text] [Related]
14. Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.
Keam B; Machiels JP; Kim HR; Licitra L; Golusinski W; Gregoire V; Lee YG; Belka C; Guo Y; Rajappa SJ; Tahara M; Azrif M; Ang MK; Yang MH; Wang CH; Ng QS; Wan Zamaniah WI; Kiyota N; Babu S; Yang K; Curigliano G; Peters S; Kim TW; Yoshino T; Pentheroudakis G
ESMO Open; 2021 Dec; 6(6):100309. PubMed ID: 34844180
[TBL] [Abstract][Full Text] [Related]
15. Indian clinical practice consensus guidelines for the management of squamous cell carcinoma of head and neck.
Prabhash K; Babu G; Chaturvedi P; Kuriakose M; Birur P; Anand AK; Kaushal A; Mahajan A; Syiemlieh J; Singhal M; Gairola M; Ramachandra P; Goyal S; John S; Nayyar R; Patil VM; Rao V; Roshan V; Rath GK
Indian J Cancer; 2020 Feb; 57(Supplement):S1-S5. PubMed ID: 32167063
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol.
Wollenberg B; Kastenbauer ; Mundl H; Schaumberg J; Mayer A; Andratschke M; Lang S; Pauli C; Zeidler R; Ihrler S; Löhrs ; Naujoks K; Rollston R
Hum Gene Ther; 1999 Jan; 10(1):141-7. PubMed ID: 10022539
[TBL] [Abstract][Full Text] [Related]
17. Hafnium oxide nanoparticles: toward an in vitro predictive biological effect?
Marill J; Anesary NM; Zhang P; Vivet S; Borghi E; Levy L; Pottier A
Radiat Oncol; 2014 Jun; 9():150. PubMed ID: 24981953
[TBL] [Abstract][Full Text] [Related]
18. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
19. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.
Grégoire V; Evans M; Le QT; Bourhis J; Budach V; Chen A; Eisbruch A; Feng M; Giralt J; Gupta T; Hamoir M; Helito JK; Hu C; Hunter K; Johansen J; Kaanders J; Laskar SG; Lee A; Maingon P; Mäkitie A; Micciche' F; Nicolai P; O'Sullivan B; Poitevin A; Porceddu S; Składowski K; Tribius S; Waldron J; Wee J; Yao M; Yom SS; Zimmermann F; Grau C
Radiother Oncol; 2018 Jan; 126(1):3-24. PubMed ID: 29180076
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress.
Martinez-Ruiz L; Florido J; Rodriguez-Santana C; López-Rodríguez A; Guerra-Librero A; Fernández-Gil BI; García-Tárraga P; Garcia-Verdugo JM; Oppel F; Sudhoff H; Sánchez-Porras D; Ten-Steve A; Fernández-Martínez J; González-García P; Rusanova I; Acuña-Castroviejo D; Carriel V; Escames G
Biomed Pharmacother; 2023 Nov; 167():115518. PubMed ID: 37717534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
